| Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? | |
| | |
MedLine Citation:
|
PMID: 20698813 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
IMPORTANCE TO THE FIELD: Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone that potentiates nutrient-induced insulin release. To date, the physiological importance of GIP has received much less attention than its younger sister incretin hormone glucagon-like peptide-1. Thus, it is worthwhile to refocus on this important and somewhat neglected incretin hormone. AREAS COVERED IN THIS REVIEW: The potential role of GIP as a treatment option for type 2 diabetes is highlighted. Furthermore, the use of GIP as a new therapeutic option for obesity, osteoporosis and cognitive impairment is also considered. WHAT THE READER WILL GAIN: Long-acting GIP receptor agonists offer a potential new class of antidiabetic drugs. Furthermore, recent observations suggest an as yet untapped potential for GIP agonists in the treatment of osteoporosis and cognitive impairment. In addition, GIP is known to play a role in lipid metabolism and fat deposition. Accordingly, both genetic and chemical ablation of GIP signalling in mice with obesity-diabetes can protect against, or reverse, many of the obesity-associated metabolic disturbances. This review focuses on preclinical data generated to date. TAKE HOME MESSAGE: GIP-based therapeutics have potential for the treatment of type 2 diabetes and obesity, with the possibility of further beneficial actions in osteoporosis and cognitive decline. |
| | |
Authors:
|
Nigel Irwin; Victor Gault; Peter R Flatt |
Related Documents
:
|
20336593 - T1r and t2r receptors: the modulation of incretin hormones and potential targets for th... 19164583 - Glp-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellu... 12488363 - Diabetes interferes with the bone formation by affecting the expression of transcriptio... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on investigational drugs Volume: 19 ISSN: 1744-7658 ISO Abbreviation: Expert Opin Investig Drugs Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-16 Completed Date: 2011-01-31 Revised Date: 2011-08-25 |
Medline Journal Info:
|
Nlm Unique ID: 9434197 Medline TA: Expert Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 1039-48 Citation Subset: IM |
Affiliation:
|
SAAD Centre for Diabetes and Pharmacy, School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, Co. Londonderry, BT52 1SA, Northern Ireland, UK. n.irwin@ulster.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alzheimer Disease*
/
drug therapy,
metabolism Animals Cell Line Diabetes Mellitus, Type 2* / drug therapy, physiopathology Gastric Inhibitory Polypeptide* / agonists, analogs & derivatives, metabolism, therapeutic use Humans Hypoglycemic Agents / therapeutic use Obesity* / drug therapy, metabolism Osteoporosis* / drug therapy, metabolism Osteoporosis, Postmenopausal / drug therapy, metabolism Receptors, Gastrointestinal Hormone / agonists, antagonists & inhibitors, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 0/Receptors, Gastrointestinal Hormone; 0/gastric inhibitory polypeptide receptor; 59392-49-3/Gastric Inhibitory Polypeptide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: ...
Next Document: New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficil...